Johnson & Johnson stock holds steady on a $60 billion 2025 revenue base

Johnson & Johnson (US4781601046) is anchored by $60.1 billion in 2025 revenue and $20.4 billion in net earnings, a scale that still defines Johnson & Johnson stock even without a fresh market quote in the available evidence. The company said full-year 2025 adjusted operational sales rose 4.1% and adjusted diluted EPS climbed 9.7% to $10.58, according to its 2025 annual report.

$60.1 billion revenue base

The 2025 annual report shows net sales of $60.1 billion, up 4.3% from $57.9 billion in 2024, while reported net earnings reached $20.4 billion versus $35.2 billion a year earlier. The difference was shaped by a 2024 gain tied to the Kenvue distribution; the company reports that adjusted results remove that item and other selected charges.

Adjusted operational sales growth of 4.1% matters more for the underlying business than the headline net-income comparison. The same report puts adjusted diluted EPS at $10.58 for 2025, up 9.7% from $9.64 in 2024, which gives a cleaner read on operating momentum.

MedTech and Innovative Medicine

Johnson & Johnson splits its business into two large engines: Innovative Medicine and MedTech. In 2025, Innovative Medicine generated $28.8 billion in sales, while MedTech produced $30.4 billion, according to the annual report.

The segment mix is almost balanced, but not identical. Innovative Medicine contributed about 48% of company sales in 2025, while MedTech accounted for roughly 51%, leaving Consumer Health as a residual legacy reference after the Kenvue separation.

Profit beat inside the report

Adjusted EPS is the number that best captures the year. At $10.58 in 2025, it was $0.94 higher than the prior year, and the 9.7% rise outpaced the 4.1% operational sales gain.

That spread suggests margin discipline and tax or mix effects mattered as much as top-line growth. The annual report also shows gross margin and operating performance improved enough to support the earnings step-up, even as reported net earnings were distorted by one-off items.

Innovative Medicine scale

Innovative Medicine is still the company s most important profit pool, with $28.8 billion in 2025 sales across prescription therapies and related products. That division remains central for investors because it combines the highest research intensity with the biggest exposure to launches, patent cycles, and litigation risk.

The company reports adjusted operational sales growth in the group, but the mix underneath matters: a stronger Innovative Medicine year can offset slower MedTech quarters. In 2025, the division was large enough to remain a meaningful driver even in a diversified portfolio of businesses.

MedTech at $30.4 billion

MedTech delivered $30.4 billion in 2025 sales and stayed slightly larger than Innovative Medicine by revenue. That scale matters because it adds a second earnings pillar at a time when the company is pushing harder into procedure-linked devices and hospital demand.

For a stock that trades on both growth and defensiveness, that balance is part of the story. The reported 4.3% increase in company sales to $60.1 billion shows the portfolio still expands even after the Kenvue separation reshaped the group.

Closing level unavailable

The latest evidence in hand supports a valuation discussion through the 2025 report rather than a current quote. On that basis, Johnson & Johnson stock is best read through $60.1 billion of sales, $20.4 billion of net earnings, and $10.58 of adjusted diluted EPS for 2025.